Crexont (IPX203) vs Rytary (IPX066)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
Crexont (IPX203)
Marketed by Amneal Pharmaceuticals and partners
NCT03670953 · Phase 3 · completed
The study was randomized, quadruple-blind, double-dummy, and active-controlled, with 506 participants entering the randomized maintenance period and 495 contributing primary-endpoint data. The clinical primary endpoint was met: IPX203 produced a significantly greater improvement in daily “good on” time than immediate-release carbidopa-levodopa (p=0.0194).
Next expected readout: February 2027 · NCT07138560 (registry estimate)
Reported efficacy
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) (Baseline (Week 7) and Week 20/ET): IPX203 - Double-Blind Maintenance — Baseline (Week 7): 11.67 hours/day (Standard Deviation 2.943); Change at Week 20/ET: -0.39 hours/day (Standard Deviation 2.706) vs IR CD-LD - Double -Blind Maintenance — Baseline (Week 7): 11.72 hours/day (Standard Deviation 2.759); Change at Week 20/ET: -0.97 hours/day (Standard Deviation 3.081) (met)
Result source: NCT03670953
Rytary (IPX066)
Marketed by Amneal Pharmaceuticals
NCT00974974 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled phase 3 trial with 393 randomized participants. The primary clinical endpoint—percentage of waking hours spent in the Parkinsonian “off” state—favored IPX066 over immediate-release carbidopa-levodopa and was statistically significant (p<0.0001).
Reported efficacy
Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): Percentage of "Off" Time During Waking Hours at End of Study (22 weeks): IPX066 23.82 percentage (Standard Deviation 14.91) vs IR CD-LD (Active Comparator) 29.79 percentage (Standard Deviation 15.81) (met)
Result source: NCT00974974
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Crexont (IPX203) | Rytary (IPX066) |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | 21.6 vs 25.5vs IR CD-LDNCT00869791 |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Crexont (IPX203)
- —Not reported
- Rytary (IPX066)
- —Not reported
ON time without troublesome dyskinesia, change
- Crexont (IPX203)
- —Not reported
- Rytary (IPX066)
- —Not reported
UPDRS Part III, change
- Crexont (IPX203)
- —Not reported
- Rytary (IPX066)
- 21.6 vs 25.5vs IR CD-LDNCT00869791
MDS-UPDRS Part II, change
- Crexont (IPX203)
- —Not reported
- Rytary (IPX066)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Crexont (IPX203): 2 of 4 rows · Rytary (IPX066): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Crexont (IPX203) | Rytary (IPX066) |
|---|---|---|
| Dropout rate | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results24.5%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 20.2%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 17.2%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 8.1% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result—IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results15.3%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 14.4%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 5.7%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 —Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence —Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence —Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence — NCT01130493 · Phase 3 · registry result, not featured evidence 2.6% NCT01096186 · Phase 3 · registry result, not featured evidence — NCT00869791 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 2%IPX203 - Dose Conversion NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more result3.1%IPX203 - Double-Blind Maintenance NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 5.5%a NCT00974974 · Phase 3 · combination · Parkinson's Disease · phase 3 show 9 more results2%390 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.8%245 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 4.6%145 mg LD NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 2.3%Part 1: Conversion NCT01411137 · Phase 3 · registry result, not featured evidence 15.6%Part 2: Open-Label Extension 1 NCT01411137 · Phase 3 · registry result, not featured evidence 25%Part 3: Open-Label Extension 2 NCT01411137 · Phase 3 · registry result, not featured evidence 1.1% NCT01130493 · Phase 3 · registry result, not featured evidence 7% NCT01096186 · Phase 3 · registry result, not featured evidence 0% NCT00869791 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | dyskinesia 6.8% nausea 4.9% dry mouth 4.2% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 1 more resultnausea 4.3% anxiety 2.7% dizziness 2.3% NCT03670953 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | show 9 more results390 mg LD nausea 20.4% (placebo 8.7%) headache 17.3% (placebo 10.9%) dizziness 12.2% (placebo 5.4%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 245 mg LD dizziness 19.2% (placebo 5.4%) nausea 19.2% (placebo 8.7%) headache 12.5% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 145 mg LD nausea 13.8% (placebo 8.7%) dizziness 9.2% (placebo 5.4%) headache 6.9% (placebo 10.9%) NCT00880620 · Phase 3 · combination · Parkinson's Disease · phase 3 upper respiratory infection 15.6% anxiety 6.3% fall 6.3% NCT01411137 · Phase 3 · registry result, not featured evidence fall 16.7% orthostatic hypotension 16.7% anxiety 8.3% NCT01411137 · Phase 3 · registry result, not featured evidence dyskinesia 4.5% confusional state 3.4% insomnia 3.4% NCT01130493 · Phase 3 · registry result, not featured evidence anxiety 3.7% fatigue 3.7% feeling of warth in abdomen 3.7% NCT00869791 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 6 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Crexont (IPX203)
Rytary (IPX066)
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
+ 4 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Crexont (IPX203)'s landscape · Rytary (IPX066)'s landscape